The term PEGylation describes the modification of biological molecules by covalent
conjugation with polyethylene glycol (PEG), a non-toxic, non-immunogenic polymer, and is …

Our understanding of the infection risks presented by tumour necrosis factor (TNF)
antagonists has continued to evolve in the 10 years since these drugs were first introduced …

Background & Aims: Interleukin-12 and interleukin-23 are inflammatory cytokines implicated
in Crohn's disease pathophysiology. Ustekinumab is a monoclonal antibody against the p40 …

Background & Aims: We performed a meta-analysis of placebo-controlled trials to evaluate
safety and efficacy of tumor necrosis factor (TNF) antagonists for Crohn's disease. Methods …

Context Maintenance therapy for Crohn disease features the use of immunosuppressive
drugs, which are associated with an increased risk of infection. Identification of safe and …

Monoclonal antibodies (mAbs) comprise the majority of protein candidates currently in
clinical development because of their versatility as therapeutic agents. While traditionally …

Background: Crohn's disease (CD) is a chronic inflammatory bowel disease usually
diagnosed in early adult life and characterized by unpredictable flares and debilitating …

Crohn's disease is a chronic, progressive, destructive disease, and current treatment
strategies are inadequate. The historic treatment goals of induction and maintenance of …

Women with inflammatory bowel disease (IBD) and the physicians who care for them must
make difficult decisions on issues of conception, pregnancy, and breastfeeding with very …

In the past few years, antagonists of tumour necrosis factor have resulted in unforetold
therapeutic benefits in Crohn's disease, but the magnitude and duration of responses are …